U-50488 is a drug which acts as a highly selective κ-opioidagonist, but without any μ-opioidantagonist effects. It has analgesic, diuretic and antitussive effects, and reverses the memory impairment produced by anticholinergic drugs. U-50488 was one of the first selective kappa agonists invented and research on its derivatives has led to the development of a large family of related compounds. This compound has never received FDA approval and there are no reported human cases in the literature involving an U-50488 overdose.
^Von Voigtlander PF, Lewis RA (1982). "U-50,488, a selective kappa opioid agonist: comparison to other reputed kappa agonists". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 6 (4–6): 467–70. doi:10.1016/S0278-5846(82)80130-9. PMID6298890.
^Hiramatsu M, Kameyama T (September 1998). "Roles of kappa-opioid receptor agonists in learning and memory impairment in animal models". Methods and Findings in Experimental and Clinical Pharmacology. 20 (7): 595–9. doi:10.1358/mf.19188.8.131.525724. PMID9819804.
^Szmuszkovicz J (1999). "U-50,488 and the kappa receptor: a personalized account covering the period 1973 to 1990". Progress in Drug Research. Fortschritte Der Arzneimittelforschung. Progres Des Recherches Pharmaceutiques. 52: 167–95. PMID10396128.
^Szmuszkovicz J (1999). "U-50,488 and the kappa receptor. Part II: 1991-1998". Progress in Drug Research. Fortschritte Der Arzneimittelforschung. Progres Des Recherches Pharmaceutiques. 53: 1–51. PMID10616295.